



GENMAB ANNOUNCES LIFT OF ZALUTUMUMAB PARTIAL CLINICAL HOLD

Summary: The FDA has lifted the partial clinical hold on zalutumumab.

Copenhagen, Denmark; July 16, 2009 – Genmab A/S (OMX: GEN) announced today that the US Food and Drug Administration (FDA) has lifted the partial clinical hold on zalutumumab studies being conducted under an US Investigational New Drug application. Enrolment of patients can now resume in the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II front line study of zalutumumab in combination with chemo-radiation.

“We have worked diligently to meet the FDA’s request for additional zalutumumab safety information and are pleased that enrolment in the studies can be resumed so quickly,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “We continue to believe zalutumumab could provide an important new treatment option for head and neck cancer patients with unmet medical needs.”

About zalutumumab

Zalutumumab is a high-affinity human antibody that targets the Epidermal Growth Factor receptor (EGFr), a molecule found in abundance on the surface of many cancer cells, and is a well validated target. Zalutumumab is in development to treat head and neck cancer and has received a Fast Track designation from the FDA covering patients with head and neck cancer who have previously failed standard therapies.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments

GENMAB ANNOUNCES LIFT OF ZALUTUMUMAB PARTIAL CLINICAL HOLD

in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™; HuMax-TF™; HuMax-Her2™; HuMax-VEGF™ and UniBody® are all trademarks of Genmab A/S. Arzerra™ is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###